These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31287788)

  • 21. Improving the prediction of the brain disposition for orally administered drugs using BDDCS.
    Broccatelli F; Larregieu CA; Cruciani G; Oprea TI; Benet LZ
    Adv Drug Deliv Rev; 2012 Jan; 64(1):95-109. PubMed ID: 22261306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential.
    Benet LZ
    J Pharm Sci; 2023 Sep; 112(9):2326-2331. PubMed ID: 37429358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System.
    Liu W; Yan T; Chen K; Yang L; Benet LZ; Zhai S
    Pharmacotherapy; 2020 Apr; 40(4):274-290. PubMed ID: 32100890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generative topographic mapping-based classification models and their applicability domain: application to the biopharmaceutics Drug Disposition Classification System (BDDCS).
    Gaspar HA; Marcou G; Horvath D; Arault A; Lozano S; Vayer P; Varnek A
    J Chem Inf Model; 2013 Dec; 53(12):3318-25. PubMed ID: 24320683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.
    Bowman CM; Benet LZ
    Drug Metab Dispos; 2016 Nov; 44(11):1731-1735. PubMed ID: 27519549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of DILI Predictive Hypotheses in Early Drug Development.
    Chan R; Benet LZ
    Chem Res Toxicol; 2017 Apr; 30(4):1017-1029. PubMed ID: 28257576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond.
    Odi R; Bibi D; Wager T; Bialer M
    Epilepsia; 2020 Aug; 61(8):1543-1552. PubMed ID: 32614073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
    Varma MV; Steyn SJ; Allerton C; El-Kattan AF
    Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems.
    Idkaidek NM
    Saudi Pharm J; 2014 Jan; 22(1):79-81. PubMed ID: 24493977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of drug metabolism for prediction of intestinal permeability (dagger).
    Chen ML; Yu L
    Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can BDDCS illuminate targets in drug design?
    Bocci G; Benet LZ; Oprea TI
    Drug Discov Today; 2019 Dec; 24(12):2299-2306. PubMed ID: 31585170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
    Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
    Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal drug transporters: an overview.
    Estudante M; Morais JG; Soveral G; Benet LZ
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1340-56. PubMed ID: 23041352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption classification of oral drugs based on molecular surface properties.
    Bergström CA; Strafford M; Lazorova L; Avdeef A; Luthman K; Artursson P
    J Med Chem; 2003 Feb; 46(4):558-70. PubMed ID: 12570377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of data mining approach to identify drug subclasses based on solubility and permeability.
    Gatarić B; Parojčić J
    Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
    Macheras P; Iliadis A; Melagraki G
    Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.
    Chan R; Benet LZ
    Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the Oral Bioavailability Correlation Between Humans and Preclinical Animals.
    Beheshti S; Shayanfar A
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):771-783. PubMed ID: 32681440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BDDCS, the Rule of 5 and drugability.
    Benet LZ; Hosey CM; Ursu O; Oprea TI
    Adv Drug Deliv Rev; 2016 Jun; 101():89-98. PubMed ID: 27182629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro disposition profiling of heterocyclic compounds.
    Keemink J; Wuyts B; Nicolaï J; Jonghe SD; Stella A; Herdewijn P; Augustijns P; Annaert P
    Int J Pharm; 2015 Aug; 491(1-2):78-90. PubMed ID: 26043826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.